Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

NCT04906876 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT04906876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2021
Completion date
July 31, 2025
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, bone sarcoma, high grade sarcoma, leiomyosarcoma, liposarcoma, metastatic sarcoma, myxofibrosarcoma, rhabdomyosarcoma, sarcoma, soft tissue sarcoma, spindle cell sarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma